Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 7/20 | 0.82 |
| ▸ | TOP2B | Q02880 | 6/20 | 0.82 |
| ▸ | KDM1A | O60341 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29536689 | 0.91 | TOP2A (1.00) | TOP2ATOP2BKDM1AMEN1KMT2A | |
| SCHEMBL1865418 | 0.91 | TOP2A (1.00) | TOP2ATOP2BKDM1AMEN1KMT2A | |
| SCHEMBL9594157 | 0.85 | TOP2A (0.81) | TOP2ATOP2BKDM1AMEN1GAA | |
| SCHEMBL9594083 | 0.84 | KDM1A (0.67) | TOP2ATOP2BKDM1A | |
| SCHEMBL8489010 | 0.84 | TOP2A (0.78) | TOP2ATOP2BKDM1AMEN1KMT2A | |
| SCHEMBL14114226 | 0.83 | TOP2A (0.71) | TOP2ATOP2BKDM1AMEN1GAA | |
| SCHEMBL5438138 | 0.81 | TOP2A (0.58) | TOP2ATOP2BKDM1A | |
| SCHEMBL6545808 | 0.81 | TOP2A (0.58) | TOP2ATOP2BKDM1A | |
| SCHEMBL8484693 | 0.81 | TOP2A (0.73) | TOP2ATOP2BKDM1A | |
| SCHEMBL34463738 | 0.81 | TOP2A (0.81) | TOP2ATOP2BKDM1AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111491-A1 | 9-aminoacridine derivatives and process for the preparation thereof | ALKBH1, ADCY9, CCR9 | TOP2A 1105/4885TOP2B 841/4885KDM1A 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.